Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma

概要

〔目的(Purpose)〕
　The objective of this study was to investigate the prognostic value of pre-lreatnient serum soluble interleukin-2 receptor (sIL-2R) level and iIs dose-dependent impact on the survival of patients with newly diagnosed follicular lymphoma (FL) grade 1-3a who required treatment at diagnosis.

〔方法ならびに成績(Methods/Results)〕
　A total of 628 patients were recorded, and 502 of these were eligible for analysis. Patients were divided into four Quartiles, based on their serum sIL-2R levels as follows: Quartile 1(sIL-2R < 520 IU/mL), Quartile 2 (520 < SIL-2R く 1030 IU/mL,Quartile 3 (1030 < SIL-2R < 2530 IU/mL) and Quartile 4 (sIL-2R > 2530 IU/mL). Using a multivariable Cox proportional-hazards model, we showed the adjusted probability of overall survival (OS) decreased with increasing serum sIL-2R levels (P for trend = 0.007). Similar trends were observed for disease-specific survival (DSS) and progression-free survival (PFS).

〔総 括(Conclusion〕
　Pre-treatment serum sIL-2R levels significantly and dose-dependently associate with worse outcomes (OS, DSS and PFS) of patients with newly diagnosed FL.